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Abstract
Percutaneous cardiopulmonary support (PCPS) has been applied for cardiopulmonary arrest
(CPA). We have developed a novel method of cardiopulmonary resuscitation using PCPS com-
bined with liposome-encapsulated hemoglobin (TRM645) to improve oxygen delivery to vital
organs. Ventricular fibrillation was electrically induced to an adult goat for 10 min. Next, PCPS
(30 ml/kg/min, V/Q: 1) was performed for 20 min. Then, external defibrillation was attempted
and observed for 120 min. The TRM group (n5) was filled with 300 mL of TRM645 for the PCPS
circuit. The control group (n5) was filled with the same volume of saline. The delivery of oxy-
gen (DO2) and oxygen consumption (VO2) decreased markedly by PCPS after CPA, compared to
the preoperative values. DO2 was kept at a constant level during PCPS in both groups, but VO2
slowly decreased at 5, 10, and 15 min of PCPS in the control groups, demonstrating that systemic
oxygen metabolism decreased with time. In contrast, the decreases in VO2 were small in the TRM
group at 5, 10, and 15 min of PCPS, demonstrating that TRM645 continuously maintained sys-
temic oxygen consumption even at a low flow rate. AST and LDH in the TRM group were lower
than the control. There were significant differences at 120 min after the restoration of spontaneous
circulation (p<0.05).
KEYWORDS: percutaneous cardiopulmonary support, liposome-encapsulated hemoglobin, car-
diopulmonary resuscitation
∗Copyright c©2008 OKAYAMA UNIVERSITY MEDICAL SCHOOL. All rights reserved
PMID:18766206
Experimental Study of a Novel Method of Cardiopulmonary  
Resuscitation Using a Combination of Percutaneous  
Cardiopulmonary Support and Liposome-encapsulated  
Hemoglobin (TRM645)
Kei Otaa,b＊,  Toshihide Mizunob,  Eisuke Tatsumib,  Nobumasa Katagirib,   
Yoshiyuki Taenakab,  Takanobu Ishizukac,  Yoshitaka Ogatac,  and Yoshihito Ujikea
aDepartment of Emergency Medicine,  Okayama University Graduate School of Medicine,   
Dentistry and Pharmaceutical Sciences,  Okayama 700-8558,  Japan,   
bDepartment of Artiﬁcial Organs,  National Cardiovascular Center Research Institute,  Suita,  Osaka 565-8565,  Japan,  and  
cResearch and Development Center,  Terumo Corporation,  Nakai-machi,  Ashigarakami-gun,  Kanagawa 259ﾝ0151,  Japan
esuscitation using percutaneous cardiopulmo-
nary support (PCPS),  which is capable of rapid 
and strong circulatory and respiratory support,  has 
been investigated for out-of-hospital cardiopulmonary 
arrest (CPA) patients admitted to emergency rooms 
[1ﾝ3].  However,  protraction of ischemia in the brain,  
heart and other vital organs,  even after initiation of 
support,  is a problem with PCPS because the ﬂow 
rate of circulatory support is low.  In this study,  to 
improve the therapeutic outcome of patients with CPA 
treated with PCPS,  liposome-encapsulated hemoglo-
bin (TRM645),  which exhibits superior ability of 
oxygen transport from red blood cells to peripheral 
tissues,  was administered simultaneously with resus-
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citation by PCPS to ensure oxygen metabolism in 
peripheral tissues under support at a low ﬂow rate.  
The eﬃcacy of this method for improving hypoxic 
conditions in the vital organs was investigated.  
TRM645 was developed and investigated by Terumo 
Corporation in cooperation with several laboratories 
[4ﾝ9].  Stroma-free hemoglobin solution was obtained 
from outdated human red blood cells [10ﾝ12].  The 
liposome particle size was about 200 nm,  which is 
1/30～40th the size of human red blood cells and is 
capable of supplying suﬃcient oxygen to peripheral 
tissues with circulatory insuﬃciency [10ﾝ12].  Thus,  
TRM645 can reach peripheral tissues that can not 
easily be reached by red blood cells,  and it is antici-
pated that these liposomes can be applied to various 
ﬁelds,  such as the treatment of cerebral infarction 
[13,  14].
　 In addition,  TRM645 has drawn attention as a 
substitute for blood transfusion because blood compat-
ibility testing is not necessary,  long-term storage for 
6 months is possible,  and infection with hepatitis B 
and C viruses or human immunodeﬁciency virus does 
not occur [15].  However,  some risks of another 
infection and uncertainty of stable blood supply still 
exist because of use of donated human blood as raw 
material [16ﾝ18].  Recombinant human hemoglobin 
and albumin-heme have already been developed as a 
totally synthetic artiﬁcial oxygen carrier.  At present,  
the feasibility of using this synthetic oxygen carrier is 
being tested in small animals,  and preparations have 
been underway to establish large-scale production 
facilities [17].
　 This study was performed based on a new concept 
that liposome-encapsulated hemoglobin as an artiﬁcial 
oxygen transporter can be used to support circulation 
and respiration at a low ﬂow rate,  increasing the 
resuscitation rate and compensating for the disadvan-
tages of PCPS.  Since only a few research facilities 
are capable of simultaneously performing these 2 
treatments,  this procedure is rarely performed.  The 
results of this study may contribute signiﬁcantly 
toward the treatment of CPA patients.
Materials and Methods
　 The experiment was performed using 10 adult 
goats (body weight±standard deviations: 59±6.5 
kg).  The goats were sedated with an intramuscular 
injection of ketamine and inhalation of isoﬂurane by a 
mask,  followed by tracheotomy and tracheal intubation 
under general anesthesia with isoﬂurane (1ｵ) and 
oxygen.  The settings for mechanical ventilation were:
fraction of inspired oxygen concentration (FIO2): 0.21,  
tidal volume: 10 mL/kg,  respiratory rate: 12/min.  
After attachment to an electrocardiograph,  the inser-
tion of aortic and central venous pressure measure-
ment lines,  and posterolateral thoracotomy,  the goats 
underwent ventricular ﬁbrillation (VF) with direct 
current electric stimulation and ventilation was sus-
pended for 10 min (CPA phase).  After the CPA 
phase,  circulation and respiration were supported for 
20 min by right atrial blood withdrawal and right 
carotid arterial blood supply (30 mL/kg/min,  V/
Q: 1.0) using a PCPS instrument (Capiox EBS,  
Terumo Corporation,  Kanagawa,  Japan) (Fig.  1).  
After 20 min of circulatory and respiratory support,  
spontaneous circulation was resumed using an external 
deﬁbrillator,  and followed for 120 min (Fig.  2).  The 
animal groups were established for circuits primed 
with 300 mL of TRM645 (TRM group,  5 animals) and 
the same volume of saline (control group,  5 animals),  
and changes in systemic oxygen metabolism induced by 
TRM645 were investigated.  TRM645 was adjusted to 
6 g/dl as the concentration of hemoglobin.  Thus 
300 mL of TRM645 contained 18 g of hemoglobin.  
Regarding the parameter measurement,  the hemody-
namic variables were measured over time immediately 
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Fig. 1　 Schematic illustration of the experimental percutaneous 
cardiopulmonary support circuit (Capiox EBS,  Terumo Corporation,  
Kanagawa,  Japan).  The circuit was placed between the superior 
vena cava via the right jugular vein for withdrawal and right carotid 
artery for supply.
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after the initiation of PCPS,  with the values before 
cardiopulmonary arrest as preoperative values.  The 
delivery of oxygen (DO2) and oxygen consumption 
(VO2) were calculated concurrently (5,  10,  and 
15 min of PCPS,  and 60 and 120 min after restora-
tion of spontaneous circulation: ROSC) as indices of 
oxygen metabolism in peripheral tissues.  DO2 and VO2 
were calculated using the following equation employing 
bypass ﬂow (BF) and arterial and mixed venous oxygen 
contents (CaO2 and CvO2):
　DO2 [mL/min]＝BF [L/min]×CaO2 [mL/dL]
×10
　VO2 [mL/min]＝BF [L/min]×(CaO2 －CvO2) 
[mL/dL]×10
　CaO2 [mL/dL]＝SaO2 [ｵ]×Hb [g/dL]×1.34
＋PaO2 [mm Hg]×0.003
　CvO2 [mL/dL]＝SvO2 [ｵ]×Hb [g/dL]×1.34
＋PvO2 [mm Hg]×0.003
　SaO2,  arterial oxygen saturation; SvO2,  mixed 
venous oxygen saturation; PaO2,  arterial partial 
oxygen pressure; PvO2,  venous partial oxygen 
pressure.
　 BF was recorded continuously using a data acquisi-
tion system (PowerLab,  ADInstruments,  Castle Hill,  
NSW,  Australia).  BF was maintained with a Doppler 
ﬂow meter（Transonic,  Transonic Systems,  Ithaca,  
NY,  USA).  Serum aspartate aminotransferase (AST) 
and lactate dehydrogenase (LDH) were measured 
periodically as parameters of organ injury by an auto-
mated chemical analyzer (DRI-CHEM3000,  Fujiﬁlm 
Medical Co.,  Ltd.,  Tokyo,  Japan).
　 The animals were cared for by a veterinarian in 
accordance with the policies and guidelines for the 
care and use of laboratory animals by the National 
Cardiovascular Center Research Institute.
Results
　 All goats resumed spontaneous circulation after 
deﬁbrillation.  The hematocrit and hemoglobin values 
were not changed by the initiation of PCPS in either 
group.  DO2 and VO2 decreased markedly during 
respiratory and circulatory support at a low ﬂow rate 
by PCPS alone after CPA,  compared to the preop-
erative values,  and the systemic oxygen transport was 
about one-half of the preoperative value.  DO2 was 
kept at an almost constant level during PCPS in both 
the control and TRM groups,  but VO2 slowly 
decreased with time to 126,  101,  and 90 mL/min at 
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Fig. 2　 Experimental procedure.  Ventricular ﬁbrillation was 
induced to a goat for 10 min.  Next,  PCPS for 20 min.  Then,  deﬁ-
brillation was attempted and observed for 120 min.  The arrow indi-
cates the point at which TRM645 was administered by PCPS.  
PCPS,  percutaneous cardiopulmonary support.
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Fig. 3　 The levels of DO2 showed no diﬀerence before CPA.  
During PCPS bypass after 10 min CPA,  DO2 in both groups were 
decreased and stayed at low levels.  VO2 in both groups were 
decreased same as DO2 after CPA.  During PCPS bypass,  VO2 
gradually decreased in the control group.  In contrast VO2 in the 
TRM group was kept stable.  CPA,  cardiopulmonary arrest; DO2,  
oxygen delivery; VO2,  oxygen consumption; PCPS,  percutaneous 
cardiopulmonary support.
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5,  10,  and 15 min of PCPS in the control groups,  
demonstrating that systemic oxygen metabolism 
decreased with time.  In contrast,  the decreases in 
VO2 were very small in the TRM group: 124,  118,  
and 117 mL/min at 5,  10,  and 15 min of PCPS,  
demonstrating that TRM645 continuously maintained 
systemic oxygen consumption under circulatory sup-
port at a low ﬂow rate (Fig.  3).
　 As for blood chemistry,  AST (49,  93,  and 104 
vs.  61,  176,  and 197 IU/L at ROSC,  60,  and 120 
min for the TRM and control groups,  respectively) 
and LDH (315,  342 and 388 vs.  370,  560 and 
633 IU/L at ROSC,  60,  and 120 min for the TRM 
and control groups,  respectively) were apparently 
lower in the TRM group 120 min after the restoration 
of spontaneous circulation.  There were signiﬁcant 
diﬀerences (Studentʼs t-test) in the values of AST and 
LDH on 120 min after the return of spontaneous cir-
culation (p＜0.05) (Fig.  4).
Discussion
　 Cardiopulmonary resuscitation by a PCPS system,  
using a combination of blood supply and withdrawal 
catheters that can be inserted percutaneously,  an 
extracorporeal membrane oxygenator,  and a centrifu-
gal pump,  is performed as an aggressive and strong 
circulatory and respiratory support method by tertiary 
emergency medical service facilities such as university 
hospitals or emergency and critical care centers.  
However,  in 2004,  only about 3,700 (about 4ｵ) of 
about 95,000 patients with out-of-hospital cardiopul-
monary arrest achieved restoration of spontaneous 
circulation and survival for 1 month in Japan [19].  
Even though spontaneous circulation can be restored 
by the application of new resuscitation methods,  
including PCPS,  complications,  such as encephalopa-
thy after resuscitation and multiple organ failure,  can 
occur,  and discharge without severe disability is dif-
ﬁcult in many cases.  Since the PCPS procedure is 
limited to the femoral arterial/venous approach in 
many cases,  it is diﬃcult to obtain an optimum ﬂow 
rate for maintaining systemic circulation; this is one 
of the causes of the low rate of discharge without 
severe disability.  In cardiopulmonary arrest patients 
who are in an extreme state of shock,  peripheral cir-
culatory insuﬃciency is marked,  and hypoxic condi-
tions in the brain and heart can be prolonged after 
PCPS.  Thus,  no marked improvement can be 
obtained with regard to social rehabilitation.  
Consequently,  there is no standard treatment at pres-
ent.  Liposome-encapsulated hemoglobin was developed 
as a temporary substitute for transfusion following 
hemorrhage [4,  7,  8].  For cardiopulmonary arrest,  
improvement of metabolism by the administration of 
liposome-encapsulated hemoglobin alone is diﬃcult 
because it is not possible to guarantee their systemic 
circulation and delivery to the whole body.  Investiga-
tion of a clinical application method to suﬃciently 
exploit the traits of liposome-encapsulated hemoglobin 
is underway.  In this study,  DO2 was decreased to half 
because of the low circulatory ﬂow rate during PCPS 
for experimental cardiopulmonary arrest.  Subse-
quently,  VO2 was maintained early after the initiation 
of PCPS,  but decreased with time even under PCPS,  
suggesting that this is one cause of the protraction of 
oxygen shortage in peripheral tissues due to the low 
ﬂow rate of circulation,  even with PCPS for cardio-
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Fig. 4　 Serum AST and LDH in the TRM group had the tendency 
to be maintained lower than the control.  The levels of serum AST 
at 120 min after the restoration of spontaneous circulation in the 
TRM group were significantly lower than the control.  
Signiﬁcance: *p＜0.05 versus control group.  Serum LDH at 
120 min after the restoration of spontaneous circulation was also 
signiﬁcantly lower in the TRM group.  Signiﬁcance: *p＜0.05 versus 
control group.  AST,  aspartate aminotransferase; LDH,  lactate 
dehydrogenase.
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pulmonary arrest or after the restoration of spontane-
ous circulation,  leading to secondary organ impair-
ment.  In the method we have proposed,  liposome-
encapsulated hemoglobin delivered oxygen to the 
peripheral tissues under low circulatory PCPS,  to 
areas at which red blood cells could not transport 
oxygen,  contributing to maintenance of systemic oxy-
gen metabolism.  This method may have reduced sec-
ondary organ injury after the restoration of spontane-
ous circulation.  This study established a novel strong 
circulatory and respiratory support method that sup-
plements the disadvantages of the 2 methods in current 
use: systemic circulation was maintained during car-
diopulmonary arrest by PCPS although the ﬂow rate 
was low,  and the oxygen supply to peripheral tissues 
was ensured using TRM645.
　 We determined the feasibility of a novel resuscita-
tion method which used PCPS and TRM645 using a 
cardiac arrest model of goats.  PCPS combined with 
TRM645 showed potential to maintain the oxygen 
delivery and consumption during early stage of ROSC 
and to prevent organ injury after resuscitation.
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